Transient benefit of amantadine in Parkinson's disease: The facts about the myth
1999; Wiley; Volume: 14; Issue: 3 Linguagem: Inglês
10.1002/1531-8257(199905)14
ISSN1531-8257
AutoresStewart A. Factor, Eric Molho,
Tópico(s)Obsessive-Compulsive Spectrum Disorders
ResumoMovement DisordersVolume 14, Issue 3 p. 515-517 Clinical/Scientific Notes Transient benefit of amantadine in Parkinson's disease: The facts about the myth Stewart A. Factor DO, Stewart A. Factor DO Department of Neurology, Albany Medical College, Albany, New York, U.S.A.Search for more papers by this authorEric S. Molho MD, Eric S. Molho MD Department of Neurology, Albany Medical College, Albany, New York, U.S.A.Search for more papers by this author Stewart A. Factor DO, Stewart A. Factor DO Department of Neurology, Albany Medical College, Albany, New York, U.S.A.Search for more papers by this authorEric S. Molho MD, Eric S. Molho MD Department of Neurology, Albany Medical College, Albany, New York, U.S.A.Search for more papers by this author First published: 23 January 2001 https://doi.org/10.1002/1531-8257(199905)14:3 3.0.CO;2-ZCitations: 12AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Citing Literature Volume14, Issue3May 1999Pages 515-517 RelatedInformation
Referência(s)